

National Jewish Health Secures Six Patents in 2010

DECEMBER 06, 2011

DENVER — In 2010, National Jewish Health was issued a total of six US patents. This number represents one of the best years on record for National Jewish, despite a severe decrease in the patent allowance rate by the USPTO in the last 10 years.

Historically, the US patent allowance rate has been stable, hovering between the low 60% and the low 70% from 1975 to 2000. However, after 2000, the allowance rate has been consistently declining to reach about 40% in 2009.

Patents issued to National Jewish Health in 2010:

National Jewish Health Inventor	Title	Patent No.	Issue Date
Dr. Erwin Gelfand	<p><i>Vaccines Using Nucleic Acid-Lipid Complexes</i></p> <p>This patent claims a new kind of vaccine, which uses a small lipid bubble to deliver an antigen and DNA adjuvant.</p>	7,741,300	06/22/2010
Dr. William Schiemann	<p><i>Cystatin C as an Antagonist of TGF-β and Methods Related Thereto</i></p> <p>This patent claims methods to identify CystC homologues that are antagonists or inhibitors of TGF-β and compositions and therapeutic methods using CystC and homologues to regulate the activity of TGF-β, and TGF-β-mediated tumor malignancy.</p>	7,749,958	07/06/2010
Dr. Donald Leung	<p><i>Cationic Steroid Antimicrobial Compositions and Methods of Use</i></p> <p>The invention provides methods for decreasing or inhibiting poxvirus infection or pathogenesis of a cell in vitro, ex vivo or in vivo.</p>	7,754,705	07/13/2010
Dr. Ronald Harbeck	<p><i>Method and Kit for Detection of Autoimmune Chronic Urticaria</i></p> <p>This patent claims a method of detecting autoimmune chronic urticaria, which will help assure many patients that dramatic changes in lifestyle are not needed to treat the condition.</p>	7,772,011	08/10/2010

Product and Method for Treatment of Conditions Associated with Receptor-Desensitization

Dr. John Cambier This patent claims the use of antibodies to desensitize B cell antigen receptors on the surface of B cells. This method has therapeutic potential for the treatment of B cell-mediated disorders like autoimmune diseases (rheumatoid arthritis, lupus etc), cancer (B cell lymphoma for example) or organ transplant rejection. 7,825,224 11/02/2010

Three-dimensional structure of TALL-1 and its cognate receptors and modified proteins and methods related thereto

Dr. Gongyi Zhang This patent relates to the use of the cytokine TALL-1 and its receptor homologues BCMA and BAFF-R as potential therapeutics for the treatment of autoimmune diseases like rheumatoid arthritis or lupus. 7,825,089 11/02/2010

National Jewish Health is the leading respiratory hospital in the nation. Founded 120 years ago as a nonprofit hospital, National Jewish Health today is the only facility in the world dedicated exclusively to groundbreaking medical research and treatment of patients with respiratory, cardiac, immune and related disorders. Patients and families come to National Jewish Health from around the world to receive cutting-edge, comprehensive, coordinated care. To learn more, visit the media resources page.

Media Contacts

Our team is available to arrange interviews, discuss events and story ideas.

William Allstetter
303.398.1002
allstetterw@njhealth.org

Adam Dormuth
303.398.1082
dormutha@njhealth.org